MedTrace Logo

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1752

Last updated 2010-09-14

No results posted yet for this study

Summary

The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

muraglitazar

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • United States
  • Argentina
  • Austria
  • Brazil
  • Canada
  • Chile
  • Germany
  • Hong Kong
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Puerto Rico
  • Russia
  • Switzerland
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00095030 on ClinicalTrials.gov